Symptom-modifying slow-acting drugs in the treatment of osteoarthritis: from molecule to clinical effect (a pharmacologist's view)
The paper systematizes data on the pharmacokinetics, molecular and cellular mechanisms of action of chondroprotectors (CPs), by using chondroitin sulfate (CS) and glucosamine (GA) as an example. It presents current ideas about the mechanisms of their absorption and penetration into the joint tissues...
Main Author: | A. S. Dukhanin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2018-06-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/830 |
Similar Items
-
SLOW-ACTING ANTI-ARTHROSIS MEDICATIONS FOR THE TREATMENT OF OSTEOARTHRITIS
by: M. S. SVETLOVA
Published: (2016-12-01) -
Strategy for the management of osteoarthritis in multimorbid patients: the balance of effectiveness and safety while choosing drug therapy
by: K. Yu. Belova, et al.
Published: (2020-08-01) -
Treatment in patients with osteoarthritis at different sites: Place of slow-acting drugs
by: N. V. Chichasova, et al.
Published: (2015-06-01) -
Advantages of osteoarthritis combined treatment with symptomatic slow-acting drugs
by: E. V. Zonova
Published: (2021-04-01) -
Cardiovascular safety and efficacy of the combined symptomatic slow-acting drug glucosamine and chondroitin sulfate in patients with gonarthrosis
by: A. P. Rebrov, et al.
Published: (2016-06-01)